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Abstract: The adenosine A2A receptor (A2AR) is in the center of a neuromodulatory network affecting a wide range of 
neuropsychiatric functions by interacting with and integrating several neurotransmitter systems, especially dopaminergic 
and glutamatergic neurotransmission. These interactions and integrations occur at multiple levels, including (1) direct re-
ceptor-receptor cross-talk at the cell membrane, (2) intracellular second messenger systems, (3) trans-synaptic actions via 
striatal collaterals or interneurons in the striatum, (4) and interactions at the network level of the basal ganglia. Conse-
quently, A2ARs constitute a novel target to modulate various psychiatric conditions. In the present review we will first 
summarize the molecular interaction of adenosine receptors with other neurotransmitter systems and then discuss the po-
tential applications of A2AR agonists and antagonists in physiological and pathophysiological conditions, such as psy-
chostimulant action, drug addiction, anxiety, depression, schizophrenia and learning and memory. 
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INTRODUCTION 
  Behavior,  mood and  cognition were previously  consid-
ered to be mainly controlled by dopaminergic and glutama-
tergic  neurotransmission.  The  ability  of  the  adenosinergic 
system to modify these behaviors and cognitive function has 
attracted  a  great  deal  of  attention  as  increasing  evidences 
support  the  tight  relationship  between  adenosine-based 
modulation and the dopaminergic and glutamatergic systems. 
Adenosine is ubiquitously distributed throughout the central 
nervous system (CNS). While early research pointed to the 
role of adenosine as a metabolite of adenosine triphosphate 
(ATP)  and  cyclic  adenosine  monophosphate  (cAMP),  the 
importance of this molecule is now widely recognized as a 
modulator  of  neurotransmission  and  complex  behaviors. 
Indeed, adenosine fulfills two important roles: (1) as a ho-
meostatic transcellular messenger in  all cells; (2) and par-
ticularly  as  a  neuromodulator  controlling  neurotransmitter 
release and neuronal excitability [31, 63]. 
  Endogenous  extracellular  adenosine,  acting  mainly 
through adenosine A1 and A2A receptors (A1Rs and A2ARs) 
in the  CNS, controls  and integrates  a wide range of brain 
functions,  most  notably  regulation  of  sleep,  locomotion, 
anxiety, cognition and memory [47, 63, 64]. Consequently, 
dysfunction of adenosinergic signaling is implicated in pa-
thologies ranging from epilepsy to neurodegenerative disor-
ders to psychiatric conditions [175]. Owning to adenosine’s 
unique  role  of  integrating  glutamatergic  and  dopaminergic 
neurotransmission  systems,  adenosine-based  therapies  are 
rapidly  evolving  in  preclinical  and  clinical  studies  for  the 
treatment  of  different  neurological  disorders  [62]  and  the  
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adenosinergic system is increasingly recognized as a poten-
tial target for the development of new therapies for psychiat-
ric disorders [32, 34]. 
  The  distribution,  molecular  structure  and  function  of 
A2ARs in the brain, has extensively been reviewed elsewhere 
[22, 32, 63, 65]. Briefly, the A2AR belongs to the G-protein 
coupled adenosine receptor family and is highly expressed in 
the  striatum  [61,  182].  A2ARs  are  also  expressed  at  lower 
levels in other brain areas, including hippocampus, cerebral 
cortex, nucleus tractus solitarius, motor nerve terminals and 
glial cells. Activation of A2ARs enhances the release of sev-
eral neurotransmitters, such as acetylcholine, glutamate and 
dopamine,  but  inhibits  gamma  aminobutyric  acid  (GABA) 
release  [24,  36,  47,  109].  A2AR  activation  also  modulates 
neuronal  excitability  and  synaptic  plasticity,  and  affects 
various behaviors including locomotor activity, sleep-wake 
cycle, anxiety, depression and learning and memory. At the 
cellular level, A2ARs are localized predominantly in the soma 
of GABAergic (enkephalin-containing, dopamine D2 recep-
tor-expressing)  striato-pallidal  projection  neurons  and  to  a 
lesser extent in asymmetrical excitatory synapses at the den-
drites of cortico-striatal terminals [7, 61, 163, 182, 203]. At 
the  molecular  level,  the  A2AR  has  been  shown  to  interact 
with  other  neurotransmitters  and  neuromodulator  receptors 
(possibly through molecular dimerization), including dopa-
mine D2 receptor (D2R), adenosine A1 receptor (A1R), can-
nabinoid CB1 receptor (CB1R), metabotropic glutamate re-
ceptor subtype 5 (mGluR5) and facilitatory nicotinic acetyl-
choline (Ach) receptor. These interactions expand the range 
of possibilities used by adenosine to interfere with neuronal 
function and communication [47, 57, 59, 181]. 
  In  the  present  overview,  we  mainly  recapitulate  some 
molecular  features  of  brain  A2ARs  and  the  ability  of  the 
A2AR  to  integrate  several  neurotransmission  and  signaling 
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interest  of  psychopharmacology,  particularly  in  psychosti-
mulation,  drug  addiction,  anxiety,  depression,  psychiatric 
disorder,  e.g.  schizophrenia,  and  in  learning  and  memory 
[185]. 
MOLECULAR  BASIS  FOR  A2AR  MODULATION  OF 
OTHER  NEUROTRANSMITTER  SYSTEMS  IN  THE 
BRAIN  
  A2ARs are highly expressed in the striatum, a pivotal lo-
cus with high levels of neurotransmission and neurotransmit-
ter receptors, thus providing an anatomical basis for the in-
teraction between the A2AR and other, such as dopaminergic 
and glutamatergic, neurotransmitter systems. These interac-
tions occur at multiple levels, including (1) direct receptor-
receptor  cross-talk  at  the  cell  membrane,  (2)  intracellular 
second  messenger  systems,  (3)  trans-synaptic  actions  via 
striatal  collaterals  or  interneurons  in  the  striatum,  (4)  and 
interactions at the network level of the basal ganglia. Com-
pared to other relatively “circumlocutory”  interactions,  the 
intramembrane receptor-receptor interactions are more direct 
in spacial connection. Agnati and Fuxe first reported experi-
mental observations for the existence of membrane receptor-
receptor interaction [1, 70, 221]. Since then, the concept has 
been further developed to receptor-receptor heteromers and 
the so called “receptor mosaic” with the discovery of aggre-
gates of multiple receptors [67, 71]. The interactions involv-
ing  the  A2ARs  have  been  described  for  several  G-protein 
coupled receptors, including D2Rs, A1Rs, CB1R and mGluR5 
[54, 181]. The largely antagonistic and occasionally syner-
gistic interactions between the A2AR and other receptors oc-
curring  directly  between  receptor  complexes  have  been 
documented. 
1. Interaction Between Adenosine A2ARs and A1Rs 
  The prevalent neuromodulatory influence of adenosine is 
inhibitory on neuronal activity in the brain [63]. Adenosine 
is known to modulate the release of many neurotransmitters, 
including dopamine, glutamate, GABA, serotonin, noradren-
aline  and  ACh,  though  the  inhibition  of  excitatory  neuro-
transmitters (e.g. glutamate) is most pronounced [31, 47, 66]. 
Adenosine modulation of neurotransmitter release is medi-
ated through the activation of the A1R and A2AR. Adenosine 
activation of Gi-coupled A1Rs reduces neurotransmitter re-
lease at pre-synaptic nerve terminals and depresses neuronal 
firing at postsynaptic sites [66, 121, 194]. In contrast, adeno-
sine activation of the Gs/olf-coupled A2AR has been demon-
strated to exert an excitatory modulation on the neurotrans-
mitter  release  of  glutamate  and  ACh  in  the  striatum,  and 
ACh in the hippocampus [33, 110]. The A2AR also controls 
GABA release in the striatum [108] as well as in the hippo-
campus [185]. Additionally, the activation A2AR decreases 
the functionality of the A1R in some experimental settings 
[46, 130, 131, 155]. 
  A1Rs and A2ARs may be activated under different condi-
tions; adenosine may preferentially act at A1Rs under basal 
condition, probably due to its relatively high expression level 
and wide-spread distribution in the brain [31, 63]. However, 
the different affinities of adenosine for A1Rs and A2ARs is 
still an open issue [35, 47]. It has been suggested that A1Rs 
largely  maintain  tonic  homoeostatic  adenosine  functions 
whereas A2ARs mostly exert its fine-tuning modulation under 
some pathophysiological situations [170, 186]. Such receptor 
discrimination may be achieved through the pattern of neu-
ronal firing (i.e. with high neuronal discharge, there may be 
higher levels of ATP and adenosine in the synapse), the dif-
ferent sources of adenosine (i.e. intra- and extracellular for-
mation), the localization of relevant synthetic or metabolic 
enzymes, or  the relative position of  adenosine release and 
receptor  sites  (synaptically  versus  extra-synaptically)  [35, 
94, 174, 184]. Furthermore, the partially overlapping distri-
butions  of  these  two  adenosine  receptors  may  also  permit 
local formation of heteromers to exert their opposite modu-
lating  effects  directly  via  a  so  called  "concentration-
dependent switch" mechanism [54]. 
2. Interaction Between Adenosine A2ARs and Dopamine 
D2Rs 
  Striatal A1Rs and  A2ARs  are  major neuromodulator re-
ceptors  that  exert  profound  effects  on  D1Rs-  and  D2R-
mediated dopamine signalling and function in the striatum. 
Evidence  suggests  the  existence  of  antagonistic  A1R-D1R 
heteromeric receptor complexes in the basal ganglia and pre-
frontal cortex, particularly in the direct striatonigral GABA 
pathways. The antagonistic A1R-D1R interactions at the neu-
rochemical and behavioral levels can be explained in part by 
the  existence of such A1R-D1R heteromeric receptor  com-
plexes  and  by  antagonistic  interactions  at  the  level  of  the 
second  messengers.  On  the  other  hand,  A2AR-D2R  hetero-
mers have been demonstrated as the first example of epitope-
epitope electrostatic interactions underlying receptor hetero-
merization  [55].  A  large  number  of  studies  with  different 
techniques,  i.e.  coimmunoprecipitation,  fluorescence  reso-
nance  energy  transfer  (FRET),  bioluminescence  resonance 
energy transfer (BRET), biochemical binding and signaling, 
microdialysis  and  behavioral  pharmacology  have  indicated 
the  existence  of  A2AR-D2R  heterodimers  in  the  striato-
pallidal GABA neurons, where activation of A2ARs reduces 
binding,  coupling  and  signaling  of  D2Rs  [18,  23,  52,  91, 
207]. However, since supporting evidence from in vivo co-
immunoprecipitation studies could be subjected to other in-
terpretations, the  evidence of A2AR-D2R dimmers  in intact 
brain tissues is still not clear yet. Further studies are needed 
to  conclusively  demonstrate  the  functional  significance  of 
receptor heterodimer in vivo. 
  The  antagonistic  A2AR-D2R  interactions  in  brain  have 
also been demonstrated at the second messenger levels [146, 
183, 199], through which the A2AR strongly modulates the 
excitability  in  the  striato-pallidal  GABA  neurons  probably 
via its ability to counteract D2R signaling to multiple effec-
tors. For example, the activation of the A2AR can counter the 
D2R-induced  inhibition  of  the  Ca
2+  influx  over  the  L-type 
voltage-dependent Ca
2+ channels (CAV 3.1 channels) via the 
activation  of  phospholipase  C  and  protein  phosphatase-2B 
[54, 90]. The counteraction of this cascade by A2ARs may 
involve Go and/or Gq11 protein with release of the βγ subunits, 
and leads to increased phosphorylation of CAV3.1 channels 
and favoring an upstate of the striatal neuronal firing [200]. 
Furthermore, the D2R-induced reduction of firing rates in the 
dopamine-denervated striatum is enhanced by A2AR antago-
nists and attenuated by A2AR agonists [199]. There also ex-Adenosine A2A Receptors in Psychopharmacology  Current Neuropharmacology, 2009, Vol. 7, No. 3    197 
ists  a  reciprocal  interaction  between  A2AR-D2R  receptors, 
through which the activation of D2Rs can inhibit the A2AR-
induced increase in cAMP accumulation via Gi/o at the level 
of adenylate cyclases [54, 69, 114].  
3. Interaction Between Adenosine A2ARs and Dopamine 
D1Rs 
  Pharmacological studies have revealed functional interac-
tion  between  A2AR  and  D1R  [144,  145,  162,  163].  At  the 
systemic level, pharmacological blockade of A2AR potenti-
ates D1R agonist-induced rotational behavior [145] and c-fos 
expression in dopamine-depleted striatum [162]. The modu-
lation of phosphorylation on neuronal dopamine and cAMP-
regulated phosphoprotein 32 (DARRP-32) by the interaction 
of A2AR and D1R has been investigated in brain slices and 
intact animals [85, 205]. DARPP-32 is expressed in the me-
dium spiny neurons of both the direct and indirect pathways. 
Stimulation  of  D1Rs  and  A2ARs  or  blockade  of  D2Rs  in-
creases DARPP-32 phosphorylation in distinct cell popula-
tions of the striatum [204]. Blockade of A2ARs or stimulation 
of D2Rs not only abolishes D2R antagonist- or A2AR agonist-
induced  DARPP-32  phosphorylation,  but  also  antagonizes 
the D1R agonist-induced DARPP-32 phosphorylation in the 
striatum [201]. Furthermore, tetrodotoxin (TTX) blocks this 
A2AR-D1R interaction, suggesting a trans-synaptic (network) 
cross-talk  between  A2ARs  and  D1Rs  [127].  Importantly, 
DARRP-32 can integrate  two distinct pathways, adenosine 
and dopamine signaling, thus providing a possible molecular 
explanation  for  the  long-known  behavioral  interaction  
between  A2ARs  and  D1Rs  [63].  Lindskog  et  al.  (2002)  
suggested  that DARPP-32 is required for A2AR  inhibition-
induced persistent motor stimulation since caffeine-induced 
motor  activity  is  greatly  reduced  in  DARPP-32  knockout 
mice  [128].  At  the  molecular  level,  caffeine  treatment  
reduces  phosphorylation  of  DARPP-32  at  the  Thr34  site 
by  blocking  A2ARs  [201].  Conversely,  caffeine  increases 
phosphorylation  of  DARPP-32  at  the  Thr75  site  via  an  
inhibitory feedback loop of protein kinase A (PKA), which 
leads to further reduction of PKA activity through feedback 
inhibition  [14,  128,  152].  Thus,  DARPP-32  appears  to  be  
an  important  molecular  target  for  integration  of  adenosine 
and  dopamine  signaling  through  phosphorylation  at  Thr34 
and Thr75 sites. 
  Recently, a genetic study of drug addiction showed that 
D1R-A2AR double knockout mice shared phenotypic similari-
ties  of  some  behavioral  components  with  A2AR  knockout 
mice or the mice with sole deficiency of D1Rs in terms of 
preference for ethanol and saccharin; whereas other compo-
nents  of  behavioral  phenotypes  in  the  D1R-A2AR  double 
knockouts were likely attributable to the loss of both recep-
tors  [191].  These  data  suggest  an  interaction  of  D1Rs  and 
A2ARs in the reinforcement processes underlying the intake 
of  rewarding  substances.  In  addition,  there  is  limited  evi-
dence for the interaction of A2AR and D3R [210]. 
4. Interaction Between A2ARs and Glutamatergic Neuro-
transmission 
  Glutamate is the main excitatory neurotransmission in the 
CNS. Glutamate activates either ionotropic receptors (includ-
ing NMDAR, AMPAR and kainate-type receptor) that  are 
mostly localized in the postsynaptic density [12] or G pro-
tein-coupled  metabotropic  glutamate  receptors  (mGluRs) 
that are mostly localized extrasynaptically [209]. A2ARs in-
teract  with  glutamatergic  system  at  several  levels  in  the 
brain. First, ultrastructural findings suggest that extra-striatal 
A2ARs are mostly synaptically-located [171], particularly in 
glutamatergic synapses [173]. These presynaptic A2ARs have 
been demonstrated to control the release of glutamate in the 
striatum,  cerebral  cortex  and  hippocampus  [24,  130,  134, 
164] and NMDAR activity in the striatum [172]. Second, it 
has been reported that A2ARs may indirectly control the level 
of extracellular glutamate by modulating the activity of glu-
tamate transporter in astrocytes [72, 154]. 
  Third, the receptor heterodimer mechanism is also sug-
gested to underline the interaction of A2AR and the glutama-
tergic system, particularly with mGluR. The immunoreactiv-
ities of A2AR and mGluR5 were found to be colocalized in 
primary cultures of striatal neurons [68] as well as in striatal 
glutamate  nerve  terminals  [177].  Furthermore,  coimmuno-
precipitation  studies  suggest  that  the  existence  of  possible 
heteromeric  receptor  complexes  containing  A2AR  and 
mGluR5,  where  synergism  may  occur  between  A2AR  and 
mGluR5 [57]. This heteromeric receptor complex is believed 
to  underlie  the  finding  that  agonists  of  A2AR  and  group I 
mGluR could synergistically reduce the affinity of D2R ago-
nist binding sites in striatal membranes [58]. 
  Fourth, concurrent stimulation of A2AR and mGluR5 re-
sults in synergistic interactions at the level of c-fos expres-
sion  and  phosphorylation  of  extracellular  signal-regulated 
kinases  (ERK)  and  DARPP-32  in  the  striatum  [57,  153]. 
Combined  A2AR  and  mGluR5  activation  have  also  led  to 
synergistic cellular effects on GABA release in the ventral 
striato-pallidal GABA neurons [44]. Recently, Coccurello et 
al. (2004) first demonstrated a synergism between A2AR and 
mGluR5 in the control of locomotion [25], which provides a 
direct functional link between A2AR  and the glutamatergic 
system and also strengthens the A2AR as potential target to 
modulate psychostimulant effects. In addition, a study from 
Schwarzschild’s group (2005) demonstrated that co-adminis-
tration of the selective mGluR5 antagonist MPEP and selec-
tive A2AR antagonist KW-6002 exerts synergistic locomotor 
stimulation in both normal and Parkinsonian mice [98]. The 
dependence  of  MPEP-induced  motor  activity  on  the  A2AR 
and mGlu5R further demonstrates the functional interaction 
between A2AR and mGluR5 at the behavioral level. 
PSYCHIATRIC  BEHAVIORAL  EFFECTS  AND 
THERAPEUTIC  POTENTIAL  OF  A2AR  MANIPULA-
TION IN THE BRAIN 
1. Psychostimulant Effects 
  A2ARs in medium spiny neurons have been established to 
be the determinant for the control of motor function, since 
A2AR ligands produce most significant motor effects [63, 64, 
181,  183]  that  were  abolished  in  mice  deficient  in  A2ARs 
[126].  In  fact,  A2AR  modulation  of  normal  or  hyperdopa-
minergic conditions is relevant to psychopharmacology [117, 
118],  whereas  the  A2AR  control  of  the  hypodopaminergic 
condition  is  directly  relevant  to  Parkinson’s  disease  (PD) 
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mechanism by which A2AR antagonists improve motor activ-
ity is proposed to be via modulation of GABA release. Thus, 
the  systemic  administration  of  A2AR  antagonists  increase 
motor activity  in animals pretreated with  D2R  antagonists, 
reserpine,  6-OH-dopamine  or  after  genetic  inactivation  of 
D2R [21, 88, 102, 161, 190, 214] or MPTP-treated monkeys 
[86, 103]. 
  On the other hand, the antagonistic interaction of A2AR-
D2R is considered to be the basis for the potential therapy of 
neuropsychiatric disorders. A2AR agonists inhibit, and A2AR 
antagonists potentiate the motor, discriminative, and reward-
ing effects of psychostimulants [60, 89, 97, 111, 160, 165, 
176, 189]. The non-selective A1R and A2AR antagonist, caf-
feine, also potentiates these effects of psychostimulants [26, 
73, 74, 143, 147]. Intriguingly, genetic inactivation of global 
A2AR or A2AR in forebrain neurons has been shown to at-
tenuate  acute  psychostimulant  effects  as  well  as  psy-
chostimulant behavioral sensitization [10, 20, 21]. To pro-
vide  an  explanation  for  the  well-known  discrepancies  - 
pharmacological blockade and genetic deletion of A2AR po-
tentiates and attenuates, respectively, psychostimulant effects 
[10, 20, 21, 60], we recently showed that the selective inacti-
vation of striatal A2ARs enhances the psychostimulant effect 
while  inactivation  of  forebrain  (including  striatal,  cortical 
and hippocampal) A2ARs attenuate psychostimulant effects. 
This study suggests that striatal A2AR and extra-striatal A2AR 
offer opposite modulation, possibly through different effects 
of pre- and post-synaptic A2ARs in the striatum [188]. 
  Furthermore, a recent coimmunoprecipitation study dem-
onstrates  that  A2ARs  are  able  to  form  receptor  complexes 
with CB1R in the rat striatum, where they are colocalized in 
dendritic processes and possibly nerve terminals [19]. Thus, 
the function of CB1R is apparently dependent on A2AR acti-
vation and modulation of A2ARs may affect the rewarding 
behavior  of  cannabinoid  [6,  219].  In  fact,  the  finding  of 
A2AR-mediated glutamate release and A2AR-CB1R interac-
tion  in  the  striatum  opens  up  an  interesting  possibility  of 
A2AR-based psychopharmacological therapy. 
2. Drug Addiction 
  Drugs of abuse have varying mechanisms of actions that 
create complex behavioral patterns related to drug consump-
tion, drug-seeking, withdrawal and relapse. The extracellular 
levels of adenosine are elevated upon exposure to drugs of 
abuse [9] and may modify addiction-related behavior [16]. 
By acting at the A2AR in the ventral striatum, modulation of 
A2AR  activity  may  influence  the  reinforcement  processes 
underlying opiate, ethanol and psychostimulant intake [17]. 
  For example, the facilitative role for the A2AR has been 
suggested in opiate reward, reinforcement as well as opiate-
seeking behavior. The A2AR agonist CGS 21680 increases, 
while the A2AR antagonist DMPX reduces,  morphine self-
administration in rats [178]. Recently, using A2AR knockout 
mice, Soria et al. (2006) showed that A2AR knockout mice 
display a lower rate of cocaine self-administration, a reduc-
tion in the maximal effort to obtain a cocaine infusion, and a 
vertical shift of the cocaine dose-response curve [196]. This 
indicates that A2ARs seem to be required to develop the ad-
dictive effects of this drug. Furthermore, decreased morphine 
self-administration, breakpoint and conditioned place prefer-
ence were also observed in A2AR knockout mice [17], These 
data support a decrease in motivation of morphine consump-
tion,  perhaps  reflecting  diminished  rewarding  effects  of 
morphine, in A2AR knockout mice. The mechanism underly-
ing attenuated reward behavior of A2AR knockout mice is not 
clear, but these findings are consistent with previous studies 
showing a synergistic rather than an antagonistic D2R-A2AR 
interaction [16]. Furthermore, a dysregulation of glutamater-
gic  signaling  caused  by  inactivation  of  presynaptic  A2AR 
could be partially responsible for this phenotype. This is in 
line with the notion that molecular adaptations of the cortico-
accumbens glutamatergic synapses are involved in compul-
sive drug seeking and relapse. 
  However, A2AR inactivation may play a differential role 
in the modulation of psychostimulant effects, depending on 
the involvement of either striatal A2ARs located on the me-
dium  spiny  neurons  themselves,  or  A2ARs  located  on  the 
cortical glutamatergic afferents that synapse on these striatal 
neurons  [188].  On  one  hand,  the  activation  of  A2ARs  can 
positively modulate glutamatergic  input  to  the nucleus  ac-
cumbens through synergistic interactions with mGluR5, and 
thus maintain a facilitative role in behavior such as psycho-
motor  sensitization  and  addictive  behavior  as  described 
above.  Alternatively,  through  antagonistic  interaction  with 
D2Rs,  activation of A2ARs  can  attenuate the rewarding ef-
fects of psychostimulant drugs. Indeed, in the study of rein-
statement of cocaine-seeking behavior [215], the A2AR an-
tagonist CGS15943 was found to reinstate cocaine-seeking 
and functions as an intravenous reinforcer, while the A2ARs 
agonist CGS21680 was found to produce a rightward shift in 
the CGS15943 reinstatement dose-effect curve. Thus, it re-
mains to be determined whether A2AR influences reward via 
striatal A2ARs or extra-striatal A2ARs. It is also possible that 
A2ARs may either directly interact with the reward (i.e. do-
pamine or opioid) system or indirectly via interaction with 
other  neurotransmitter  systems  such  as  glutamate  or  can-
nabinoids in the brain. 
3. Anxiety 
  Clinical  investigations,  pharmacological  studies  and 
models  of  genetically  modified  rodents  have  implicated 
adenosine receptors in the etiology and modulation of vari-
ous  types  of  anxiety.  Caffeine  and  alcohol  have  been  in-
volved in anxiety-related behavior, due to their antagonism 
at adenosine receptors and ability to increase adenosine lev-
els, respectively. The adenosine effects on anxiety have been 
partly  attributed  to  the  anxiogenic  effects  of  A1R  antago-
nism. However, there are several lines of evidence indicating 
the involvement of the A2AR in anxiety. First, spontaneous 
anxiety-like  behavior  is  enhanced  in  A2AR  knockout  mice 
compared to their WT littermates [13, 15, 122], indicating 
that adaptive mechanisms in A2AR knockouts may result in 
increased  propensity  for  anxiety.  Second,  human  genetic 
association  studies  indicate  the  association  between  A2AR 
gene  polymorphisms  and  caffeine-induced  anxiety  [4,  5, 
211]. Third, pharmacological studies with caffeine suggest 
the  involvement  of  adenosine  receptor  in  anxiety-related 
behavior. It is reported that adenosine has anxiolytic effects, 
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theophylline  [113].  Similarly,  caffeine  and  theophylline  at 
higher  doses  showed  anxiogenic  effects,  suggesting  that 
blockade  of  adenosine  receptors  after  chronic  ingestion  of 
caffeine led to increased anxiety-related behavior. However, 
it should be noted that caffeine effects on anxiety are dose 
related:  higher  doses  of  caffeine  tend  to  increase  [83,  84, 
115, 129, 192, 198] and lower doses of caffeine tend to re-
duce  anxiety  levels  in  humans  [87,  124,  125].  The  dose-
dependent effect of caffeine may due to different effects of 
caffeine  on  different  subtypes  of  adenosine  receptors  in 
anxiety. Fourth, El Yacoubi et al. (2000) also showed that 
the short-term anxiety-like effect of caffeine in mice might 
not be related solely to the blockade of A2AR, since it is not 
shared by A2ARs  selective  antagonists [50].  Therefore,  the 
role of A2AR in anxiety remains to be defined [27]. 
4. Depression 
  The effect of the adenosine modulation on depression is 
complex due to the participation of several neurotransmis-
sion systems, such as dopaminergic and serotoninergic sys-
tems as well as the corticotrophin system [34, 75, 96, 179]. 
The involvement of adenosine in depression has also been 
supported by other indirect evidence showing that classical 
tricyclic antidepressants, such as nortriptiline, chlomipramine 
or desipramine, can bind to adenosine receptors and reduce 
the activity of ecto-nucleotidases in cortical nerve terminals 
[41].  Thus,  the  classical  antidepressants  also  reverse  the 
adenosine-induced  immobility  [112,  113].  However,  the 
pharmacological  effect  of  adenosine  on  depression  is  not 
clear yet. A series of studies showed that administration of 
adenosine,  either  peripherally  or  intra-cerebroventricularly, 
has an antidepressant effect, which involves the recruitment 
of adenosine receptors, the NO-cGMP system, or the opioid 
system [104-106]. However, other studies found that adeno-
sine and its analogues caused depressant-like behavioral ef-
fects by increasing immobilization time in rats submitted to 
inescapable  shocks  and  forced  swim  tests  [93,  141,  142, 
217]. 
  At the receptor level, the blockade of A2ARs relieves the 
early stress-induced loss of synaptophysin, a synaptic marker, 
in the hippocampus of rats subjected to sub-chronic restraint 
stress [30]. A2AR antagonists prolong escape-directed behav-
ior in the tail suspension and forced swim tests [49]. Addi-
tionally, A2AR knockout mice displayed an attenuated ‘be-
havioral despair’ in these two screening tests [48]. The same 
research group furthermore demonstrated that haloperidol (a 
D2R antagonist) prevented the antidepressant effects result-
ing from A2ARs blockade [48, 49]. This evidence suggests a 
potential role of A2AR modulation as novel anti-depressant 
target. 
  However,  mechanisms  by  which  the  A2AR  exerts  its 
modulation  of  depression  are  not  clear  yet,  but  adenosine 
modulation of the serotoninergic system may in part be re-
sponsible [78]. For example, adenosine receptors have been 
shown to control the release of serotonin [156]. Furthermore, 
caffeine, probably via blockade of A2AR, relieves restraint-
induced stress, which correlates with reduction of serotonin 
levels in the hippocampus [218]. Given the increasingly rec-
ognized role of neurogenesis and neuronal trophic factors in 
the depression-related behavior [136, 137], it is interesting to 
note the novel interaction between A2ARs and Trk-B recep-
tors [95], and neurotrophins, such as brain-derived neurotro-
phic factor (BDNF) [45, 123], which may provide another 
potential mechanism for the involvement of A2ARs in anxiety 
modulation. Thus, beyond interaction with D2Rs, the interac-
tion of the A2AR with other neurotransmitter systems, such as 
glutamatergic,  serotoninergic, and corticotrophin system  as 
well as trophic factors should be examined. 
5. Schizophrenia 
  Schizophrenia  is  a  complex  neuropsychiatric  disorder 
characterized by cognitive deficits, and positive and negative 
symptoms  [99,  150].  Almost  all  antipsychotics  currently 
used  in  clinical  practice  are  dopamine  D2R  antagonists, 
though they produce many side effects. The development of 
novel pharmacological targets for antipsychotics is still very 
limited, primarily due to the heterogeneity, lack of solid ana-
tomical or neurochemical basis of the disorder, and lack of 
an adequate animal model that faithfully mimics the features 
of behavioral changes found in this psychiatric disorder [28, 
51, 100, 101]. To date, many biochemical and neurochemical 
markers as well as a rather broad brain area have been impli-
cated  in  the  pathogenesis  of  diverse  psychiatric  disorders 
[11,  133,  149,  195,  197].  On  the  other  hand,  the  current 
evaluation of the efficacy of novel antipsychotics still largely 
relies on the alleviation of behavioral changes that character-
ize schizophrenia. 
  Recent progress in adenosine neurobiology supports the 
notion of adenosine-based therapy and the A2AR as a novel 
therapeutic target for the treatment of psychiatric disorders. 
The first  line of evidence came from pharmacological and 
genetic  studies  showing  that  A2AR  activity  affects  schizo-
phrenia-like behaviors in patients. Caffeine exacerbates posi-
tive  symptoms  [39,  132,  138,  140,  151]  of  schizophrenia, 
whereas  adenosine  transport  inhibitors  (such  as  dipyrida-
mole) and xanthine oxidase inhibitors (such as allopurinol) 
may  be  beneficial  for  schizophrenia  [2,  3].  Intriguingly,  a 
clinical report suggests that poorly responsive schizophrenic 
patients  improved  considerably  with  add-on  of  allopurinol 
[116]. Early studies found that a single-nucleotide polymor-
phism (SNP) of the A2AR gene was a candidate for a schizo-
phrenia  susceptibility  gene  on  chromosome  22q12-13  [42, 
92], but this has not been replicated by others. Furthermore, 
theophylline was shown to mimic deficiency of sensorimotor 
gating [77], as evaluated by a disturbed prepulse inhibition 
or P50 evoked potential found in schizophrenic individuals 
[167]. These observations of clinical genetics warrant further 
investigation. 
  Second, the adenosine-hypofunction hypothesis of schizo-
phrenia is further supported by studies from Yee et al. (2007) 
[220] using a transgenic mouse model with overexpression 
of adenosine kinase, causing decreased adenosine levels in 
forebrain. They demonstrated that subtle changes in adeno-
sine levels in forebrain could lead to the emergence of be-
havioral  endophenotypes  implicated  in  schizophrenia  and 
abnormal  response  to  psychostimulants,  i.e.  amphetamine 
and MK-801 [220]. It is also reported that startle habituation 
(a measure of sensorimotor function) was reduced by A2AR 
antagonists  [148]  and  genetic  deletion  of  A2ARs  in  mice 
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A2ARs in the pathophysiology of schizophrenia came from 
observations that treatment with antipsychotic drugs alter the 
adenosinergic system in animals and in humans [4, 135, 148, 
159, 213]. It was also observed that clozapine, an atypical 
antipsychotic, induced c-fos expression that could be blocked 
by A2AR antagonists in rodents [159]. In addition, this clo-
zapine-induced  antipsychotic  effect  also  affects  the  ecto-
nucleotidase pathway,  thus consequently  modulates adeno-
sine levels and resulting activation of A2ARs [119]. In clini-
cal studies, Martini et al. (2006) demonstrated an upregula-
tion of A2AR in platelets from patients under treatment with 
haloperidol,  a  typical  antipsychotic  [135].  This  study  also 
revealed  the  co-expression  of  A2ARs  and  D2Rs  assembled 
into heteromeric complexes in human platelets. Conversely, 
chronic treatment with non-dopamine based atypical antip-
sychotic was not able to induce any significant alterations in 
A2AR equilibrium binding parameters and receptor respon-
siveness. In line with this finding, an upregulation of striatal 
A2ARs has been demonstrated to occur in schizophrenia pa-
tients  with  antipsychotic  treatment  [4].  Noticeably,  the  in-
creased  A2AR  density  correlated  with  the  dose  of  antipsy-
chotics in chlorpromazine equivalents, which suggests a role 
of A2ARs in the molecular effects of antipsychotic drugs. 
  The fourth line of evidence came from molecular studies 
suggesting a modulatory role of A2ARs as a fine-tuner in re-
balancing an impaired glutamatergic-dopaminergic commu-
nication. Regarding dopaminergic function, the antagonistic 
interaction  of  A2AR-D2R  in  the  striatum  suggested  anti-
psychotic  behavior  in  schizophrenia  by  A2AR  agonist  to 
function as a dopamine receptor antagonist. The activation of 
A2ARs can reduce D2R affinity and function, which may po-
tentially underlie the antipsychotic-like profile of adenosine 
agonists [56], the hyperdopaminergic effect of caffeine [53, 
56] and the exacerbation of psychotic symptoms by caffeine 
in schizophrenic patients [132]. More data discussed in other 
reviews  suggested  the  relationship  between  hyperdopa-
minergic transmission and unbalanced adenosinergic modu-
lation in the striatum [82, 120, 187, 202]. These observations 
support the possibility that the manipulation of A2ARs (by 
activation  of  A2AR)  may  help  restore  an  adequate  dopa-
minergic signaling.  Regarding glutamatergic function, A1R 
and A2AR agonists have both been shown to prevent behav-
ioral and EEG effects induced by NMDAR antagonists [166, 
193]. In an NMDAR hypofunction model of schizophrenia 
[157], the function of NMDARs could be modified by both 
A1R and A2AR  activities [40, 76, 172, 208, 216].  Further-
more, both A1Rs and A2ARs control the evoked release of 
glutamate in striatum [24, 177]. Conversely, the activation of 
the NMDAR increases the adenosine tone [139], while inhi-
bition of the NMDAR reduced adenosine release [43]. Im-
portantly,  the  psychostimulant  effects  of  NMDAR  antago-
nists are largely abolished by genetic inactivation or pharma-
cological blockade of A2ARs [176, 188]. These studies sug-
gest that modulation of A2ARs may re-balance the hypofunc-
tion of NMDARs in models of schizophrenia. As reviewed 
in  the  above  sections,  the  existence  of  heteromeric  A2AR-
D3R  and  A2AR-mGluR5  receptor  complexes  may  also 
strengthen the potential modulation of A2AR on schizophre-
nia therapy [206]. 
  However, the effect of adenosine modulation on psychi-
atric disorders is likely more complex, with involvement of 
different neurotransmitter systems in various brain regions. 
For example, we recently demonstrated that striatal deletion 
of A2ARs enhances the actions of psychostimulants, whereas 
deletion  of  A2ARs  in  forebrain  (including  striatum,  cortex 
and hippocampus) attenuates the effect of psychostimulants. 
These  data  suggest  that  striatal  A2ARs  and  extra-striatal 
A2ARs exert different effects on psychomotor activity. Thus, 
adenosine-based  psychopharmacological  therapy  may  rely 
on the status or degree of dysfunction in other neurotransmit-
ters, or spatial targeting of adenosine agonists/antagonists, or 
drug specificity, selectivity, dosage and paradigm. 
6. Learning and Memory 
  Several recent pharmacological and genetic studies sug-
gest a potential modulatory role of brain A2AR activity on 
learning, memory, and other cognitive process [34, 181]. For 
example, local administration of A2AR agonists into the pos-
terior  cingulate  cortex  impaired  memory  retrieval  in  rats 
[158]. Conversely, the A2AR antagonist SCH58261
 and caf-
feine have been shown to improve social recognition mem-
ory  [169]  and  improve  memory  performance  in  rodents 
through  different  tasks  [206].  Genetic  inactivation  of  the 
A2ARs  enhanced  spatial  recognition  memory  and  novelty 
exploration in Y-maze testing in mice [212]. Recently, two 
studies  demonstrated  that  both  pharmacological  blockade 
and  genetic  inactivation  of  A2ARs  attenuated  β-amyloid-
induced memory loss [29, 37]. The above results suggest that 
the A2AR activity can modify the spatial memory process in 
rodents.  
  On the other hand, working memory primarily depends 
on  the  integrity  of  prefrontal  cortical  function  [80]  and  is 
critical to human reasoning and judgment,  which  is  at  the 
core of pathophysiology for many neuropsychiatric disorders 
such as Alzheimer’s disease [8, 107, 126] and schizophrenia 
[81].  The  control  of  working  memory  by  A2ARs  [169]  is 
supported by several elegant behavioral studies showing an 
impact  of  caffeine  [168].  Recently,  transgenic  overexpres-
sion of A2ARs  in  cortex has been  shown to  impair spatial 
working  memory  in  radial  maze,  repeated  trials  of  Morris 
water  maze  and  objective  recognition  tests  [79].  In  agree-
ment with  this finding, we recently observed (unpublished 
data)  that  genetic  inactivation  of  A2ARs  significantly  im-
proved working memory; furthermore, the improved work-
ing memory was selective for this specific short-term mem-
ory  whereas  the  performance  of  spatial  reference  memory 
and  the  memory  retention  after  prolonged  training  was 
largely indistinguishable between A2AR knockout mice and 
their WT littermates. These results suggest a selective modu-
latory role of A2AR activity in working memory.  
CONCLUDING REMARKS 
  In this review, we have described the role of adenosine 
A2A receptor-driven interactions with other neurotransmitter 
systems, at multiple levels of psychopharmacology, from the 
molecular basis of receptor-receptor  cross-talk, to pharma-
cological  and  genetic  manipulations  of  A2AR  activity,  and 
the  alteration  of  neuropsychiatric  phenotypes  in  psy-
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nia and learning and memory. Based on the literature to date, 
the A2AR  is involved in multiple receptor-receptor interac-
tions,  multiple  neurotransmissions  and  multiple  neuropsy-
chiatric disorders. In particular, it tightly interacts with two 
main neurotransmitter systems, the dopaminergic and gluta-
matergic  signaling  pathways,  with  implications  for  a  wide 
range of psychiatric behaviors and several psychiatric disor-
ders.  Hence,  A2ARs  are  ideally  positioned  as  a  fine-tuner, 
providing integrated effects between glutamatergic and do-
paminergic signaling, and may represent a novel neuropsy-
chopharmacology target. 
  Despite its  attractive therapeutic potential, several con-
cerns  need  to  be  introduced,  when  evaluating  the  putative 
role(s) of A2ARs in psychopharmacology. First, since adeno-
sine system works via neuromodulation, the modulatory abil-
ity of the adenosine system (including  the A2AR) may de-
pend on and may intricately be linked with the activity of 
other “potent” neurotransmission systems, i.e. dopaminergic, 
glutamatergic and serotoninergic systems. Second, a primary 
role of the adenosine neuromodulatory system seems to be 
maintenance of homeostasis or promotion of the adaptation 
of  multiple  neurotransmitter  systems  in  the  brain.  Thus, 
adenosine, and A2ARs in particular, seem to curtail extremes 
(i.e. over-stimulation or under-stimulation) of  these neuro-
transmitter  systems  in  the  brain.  A2AR-based  modulation 
may largely be exerted, once disequilibrium of neurotrans-
mitter systems occurs. Third, extracellular adenosine may act 
at A2ARs and A1Rs with globally opposite functions, or may 
act at the A2AR in different brain regions with its differential 
action to exert modulating effects. The balanced outcome of 
adenosine actions may be in part controlled by neuroadapta-
tion or maladaptation of neurotransmission, by which it ex-
erts its effect and may in part depend on the preferential sites 
of pharmacological reagent activity. 
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